Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination With Palbociclib in Women With ER Positive, HER2 Negative Advanced Breast Cancer

Trial Profile

A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination With Palbociclib in Women With ER Positive, HER2 Negative Advanced Breast Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2019

At a glance

  • Drugs AZD 9833 (Primary) ; Palbociclib
  • Indications Adenocarcinoma; Advanced breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Jan 2019 Planned End Date changed from 30 Jun 2020 to 30 Nov 2021.
    • 08 Jan 2019 Planned primary completion date changed from 30 Jun 2020 to 30 Nov 2021.
    • 02 Nov 2018 Planned number of patients changed from 240 to 165.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top